Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
IOVA
SELLIovance Biotherapeutics, Inc. · Healthcare · United States · $2.2B · Avg Vol: $77M/d
COMPANY DESCRIPTION
Iovance Biotherapeutics, Inc. is a pioneer in the development of tumor-infiltrating lymphocyte (TIL) therapies for patients with solid tumor cancers. The company's competitive moat is its first-mover advantage, proprietary manufacturing processes, and FDA approval for Amtagvi, the first cellular therapy for a solid tumor. It operates as a leading-edge biotechnology player in the oncology space.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 1.2M | 164.1M | 263.5M | 1388.7% | 285.6M | 362.1M | 496.3M | 37.2% |
| EPS | -1.05 | -1.89 | -1.28 | -1.09 | — | -0.92 | -0.56 | -0.32 | — |
| Shares | 446.5M | 256.1M | 305.3M | 411.9M | -7.7% | 446.5M | — | — | — |
| Debt | 85.4M | 75.9M | 58.3M | 49.4M | -16.7% | 47.8M | — | — | — |
| Equity | 499.6M | 584.6M | 710.4M | 698.6M | 11.8% | — | — | — | — |
| Op CF | -292.8M | -361.8M | -353.0M | -302.4M | — | -270.8M | — | — | — |
| Inv CF | 256.5M | -155.2M | -96.4M | 47.5M | — | — | — | — | — |
| Fin CF | 190.2M | 463.0M | 390.7M | 300.8M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of IOVA are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| IOVA | Iovance Biotherapeutics, Inc.(you) | $2.2B | 35 | SELL |
| AGIO | Agios Pharmaceuticals, Inc. | $2.2B | 34 | SELL |
| SLS | SELLAS Life Sciences Group, Inc. | $2.2B | 37 | HOLD |
| ADMA | ADMA Biologics, Inc. | $1.9B | 35 | HOLD |
| TRVI | Trevi Therapeutics, Inc. | $2.5B | 36 | HOLD |
| RAPP | Rapport Therapeutics, Inc. | $1.9B | 33 | SELL |
| DMRA | Damora Therapeutics, Inc. | $1.8B | 34 | SELL |
| NRIX | Nurix Therapeutics, Inc. | $2.4B | 30 | SELL |
| NUVB | Nuvation Bio Inc. | $2.2B | 28 | SELL |
| BCAX | Bicara Therapeutics Inc. | $1.8B | 32 | SELL |
Peer medians: ROE -25.5% · P/E 27.6x · Gross margin 50.7%